Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037258 | 0.79 | BRAF (0.34) | — | |
| SCHEMBL2403292 | 0.79 | KMT2A (0.38) | POLBMAPTMEN1NPC1RAB9A | |
| SCHEMBL2440172 | 0.76 | L3MBTL1 (0.42) | POLBL3MBTL1MAPTNOX1MEN1 | |
| SCHEMBL6098360 | 0.72 | POLB (0.44) | POLBL3MBTL1MAPTNOX1MEN1 | |
| SCHEMBL18207456 | 0.71 | ALDH1A1 (0.39) | L3MBTL1MAPTMEN1NPC1KMT2A | |
| SCHEMBL6834283 | 0.70 | POLB (0.51) | POLBL3MBTL1MAPTHSD17B10 | |
| SCHEMBL23387943 | 0.69 | SYK (0.32) | ALDH1A1 | |
| SCHEMBL4518931 | 0.69 | POLB (0.42) | POLBL3MBTL1MAPTNOX1MEN1 | |
| Hydrochloric Acid SCHEMBL6264261 | 0.69 | POLB (0.50) | POLBL3MBTL1MAPTHSD17B10KDM4E | |
| SCHEMBL7992753 | 0.69 | POLB (0.42) | POLBL3MBTL1MAPTNOX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842803-B2 | Imidazopyridines Syk inhibitors | Kronos Bio, Inc. (US) | 2020-11-24 | — | — | US | claimed |
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2019-04-25 | — | — | US | claimed |
| EP-2545052-B1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2014-11-12 | — | — | EP | claimed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | claimed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | claimed |
| EP-2545052-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | Kronos Bio, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-9562056-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2545052-B1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2545052-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | POLB 2685/4885L3MBTL1 3280/4885MAPT 4056/4885 |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | POLB 2685/4885L3MBTL1 3280/4885MAPT 4056/4885 |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | POLB 2685/4885L3MBTL1 3280/4885MAPT 4056/4885 |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | POLB 2378/4885L3MBTL1 3833/4885MAPT 3496/4885 |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | POLB 2378/4885L3MBTL1 3833/4885MAPT 3496/4885 |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | POLB 2685/4885L3MBTL1 3280/4885MAPT 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.